Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pizzuti, Laura, Marchetti, Paolo, Natoli, Clara, Gamucci, Teresa, Santini, Daniele, Scinto, Angelo Fedele, Iezzi, Laura, Mentuccia, Lucia, D’Onofrio, Loretta, Botticelli, Andrea, Moscetti, Luca, Sperati, Francesca, Botti, Claudio, Ferranti, Francesca, Buglioni, Simonetta, Sanguineti, Giuseppe, Di Filippo, Simona, di Lauro, Luigi, Sergi, Domenico, Catenaro, Teresa, Tomao, Silverio, Giordano, Antonio, Maugeri-Saccà, Marcello, Barba, Maddalena, Vici, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587713/
https://www.ncbi.nlm.nih.gov/pubmed/28878375
http://dx.doi.org/10.1038/s41598-017-10061-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587713/
https://www.ncbi.nlm.nih.gov/pubmed/28878375
http://dx.doi.org/10.1038/s41598-017-10061-2

Ejemplares similares